Advertisement

Journal of Neuro-Oncology

, Volume 65, Issue 2, pp 167–172 | Cite as

Response of Neoplastic Meningitis from Solid Tumors to Oral Capecitabine

  • Pierre Giglio
  • Ivo W. Tremont-Lukats
  • Morris D. Groves
Article

Abstract

Neoplastic meningitis (NM) is a major challenge for the neuro-oncologist as it constitutes a relatively common clinical problem in systemic and central nervous system cancers, and is very difficult to treat. NM portends a significant worsening in prognosis. Chemotherapeutic treatment options are limited, and not particularly effective. We report two cases of NM from breast carcinoma and a third with esophageal carcinoma, which responded to treatment with capecitabine, an oral prodrug for 5-flurouracil. We believe capecitabine warrants further investigation in patients with NM. In some patients, its use may result in clinical and radiographic tumor responses, improved quality of life, and possibly increased survival.

breast cancer capecitabine chemotherapy gastroesophageal cancer neoplastic meningitis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Grossman SA, Krabak MJ: Leptomeningeal carcinomatosis. Cancer Treat Rev 25: 103–119, 1999Google Scholar
  2. 2.
    Baculi RH, Suki S, Nisbett J, Leeds N, Groves M: Meningeal carcinomatosis from breast carcinoma responsive to trastuzumab. J Clin Oncol 19: 3297–3298, 2001Google Scholar
  3. 3.
    Yap HY, Yap BS, Tashima CK, DiStefano A, Blumenschein GR: Meningeal carcinomatosis in breast cancer. Cancer 42: 283–286, 1978Google Scholar
  4. 4.
    Trump DL, Grossman SA, Thompson G, Murray K, Wharam M: Treatment of neoplastic meningitis with intraventricular thiotepa and methotrexate. Cancer Treat Rep 66: 1549–1551, 1982Google Scholar
  5. 5.
    Esteva FJ, Soh LT, Holmes FA, Plunkett W, Meyers CA, Forman AD, Hortobagyi GN: Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer. Cancer Chemother Pharmacol 46: 382–386, 2000Google Scholar
  6. 6.
    Ogawa K, Toita T, Sueyama H, Fuwa N, Kakinohana Y, Kamata M, Adachi G, Saito A, Yoshii Y, Murayama S: Brain metastases from esophageal carcinoma: natural history, prognostic factors, and outcome. Cancer 94: 759–764, 2002Google Scholar
  7. 7.
    Blum JL: The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer. Oncologist 6: 56–64, 2001Google Scholar
  8. 8.
    Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin 172 as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19: 2282–2292, 2001Google Scholar
  9. 9.
    Dooley M, Goa KL: Capecitabine. Drugs 58: 69–76, 1999Google Scholar
  10. 10.
    Johnston PG, Kaye S: Capecitabine: a novel agent for the treatment of solid tumors. Anticancer Drugs 12: 639–646, 2001Google Scholar
  11. 11.
    Danenberg K, Metzger R, Salonga D: Thymidine phosphorylase expression in colorectal tumours together with that of thymidylate synthase predict tumor response to 5-fluorouracil. Am Assoc Cancer Res Annu Meet 38: 614–615, 1997Google Scholar
  12. 12.
    Kitazono M, Takebayashi Y, Ishitsuka K, Takao S, Tani A, Furukawa T, Miyadera K, Yamada Y, Aikou T, Akiyama S: Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase. Biochem Biophys Res Commun 253: 797–803, 1998Google Scholar
  13. 13.
    Takebayashi Y, Natsugoe S, Baba M, Akiba S, Fukumoto T, Miyadera K, Yamada Y, Takao S, Akiyama S, Aikou T: Thymidine phosphorylase in human esophageal squamous cell carcinoma. Cancer 85: 282–289, 1999Google Scholar
  14. 14.
    Igarashi M, Dhar DK, Kubota H, Yamamoto A, El-Assal O, Nagasue N: The prognostic significance of microvessel density and thymidine phosphorylase expression in squamous cell carcinoma of the esophagus. Cancer 82: 1225–1232, 1998Google Scholar
  15. 15.
    Takebayashi Y, Yamada K, Miyadera K, Sumizawa T, Furukawa T, Kinoshita F, Aoki D, Okumura H, Yamada Y, Akiyama S, Aikou T: The activity and expression of thymidine phosphorylase in human solid tumours. Eur J Cancer 32A: 1227–1232, 1996Google Scholar
  16. 16.
    Shimada H, Takeda A, Shiratori T, Nabeya Y, Okazumi S, Matsubara H, Funami Y, Hayashi H, Gunji Y, Kobayashi S, Suzuki T, Ochiai T: Prognostic significance of serum thymidine phosphorylase concentration in esophageal squamous cell carcinoma. Cancer 94: 1947–1954, 2002Google Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  • Pierre Giglio
    • 1
  • Ivo W. Tremont-Lukats
    • 1
  • Morris D. Groves
    • 1
  1. 1.Neuro-Oncology DepartmentUniversity of Texas – M.D. Anderson Cancer CenterUSA

Personalised recommendations